Lit Matters 2: Why You Should Consider Doxy For CAP

Macrolide resistance has changed first-line outpatient treatment for community-acquired pneumonia. In mild-to-moderate adult CAP, doxycycline remains a credible option with strong oral bioavailability, lung penetration, and activity against typical and atypical respiratory pathogens.

Doxycycline for Mild CAP

• Guideline-era antibiotic choice: Rising macrolide-resistant S. pneumoniae has pushed CAP treatment toward amoxicillin or respiratory fluoroquinolones, making doxycycline an appealing middle ground with broader pathogen coverage.
• Target patient population: The evidence applies to adults with mild-to-moderate community-acquired pneumonia, not ICU patients, shock, mechanical ventilation, or combination-antibiotic regimens.
• Clinical cure performance: Across 6 randomized trials with 834 patients, doxycycline monotherapy achieved clinical cure rates comparable to fluoroquinolones or macrolides at end of treatment.
• Safety and tolerability signal: Adverse event rates were similar to comparator antibiotics, supporting doxycycline's reputation as a generally well-tolerated option for non-severe CAP in adults.
• Practical advantages: Doxycycline offers excellent oral bioavailability, good lung tissue penetration, and convenient twice-daily dosing, with cost advantages over levofloxacin highlighted in the chapter.